A Phase 3 interventional study of Brexpiprazole in Schizophrenia, sponsored by H. Lundbeck A/S. Completed at 48 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-27.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 14th largest by enrollment, is one of 6 that started in 2013, is one of 16 in phase 3, and was the 14th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 6 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
29 studies in Schizophrenia by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 28 finished, 9 (32%) have results posted.
Among the 29 studies in Schizophrenia by H. Lundbeck A/S, this one is the 12th largest by enrollment of the 28 interventional ones that give a count, is one of 6 that started in 2013, is one of 16 in phase 3, and was the 17th registered.
H. Lundbeck A/S’s Schizophrenia studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 29 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To determine the safety and efficacy of brexpiprazole during long-term treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Brexpiprazole
1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
Safety and Tolerability
Number of treatment-emergent adverse events (TEAEs)
Time frame: Up to 52 weeks and a safety follow-up by telephone contact or clinic visit after 30 days after the last dose of investigational medicinal product (IMP)
| Milestone | Brexpiprazole |
|---|---|
| Started | 210 |
| Completed | 101 |
| Not completed | 109 |
| Withdrew: Adverse event | 32 |
| Withdrew: Withdrawal by subject | 22 |
| Withdrew: Lack of efficacy | 12 |
| Withdrew: Lost to follow-up | 10 |
| Withdrew: Protocol violation | 5 |
| Withdrew: Non-compliance with imp | 4 |
| Withdrew: Adminstrative or other reason(s) | 23 |
| Withdrew: Enrolled, not treated | 1 |
Number of treatment-emergent adverse events (TEAEs)
| TEAEs | Brexpiprazole |
|---|---|
| Safety and Tolerability | 337 |
Collected over Baseline to end of study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole | — | 31/209 (14.8%) | 47/209 (22.5%) |
| Event | Brexpiprazole |
|---|---|
| SchizophreniaPsychiatric disorders | 18/209 |
| Psychotic disorderPsychiatric disorders | 2/209 |
| Suicidal ideationPsychiatric disorders | 2/209 |
| Social stay hospitalisationSocial circumstances | 2/209 |
| PregnancyPregnancy, puerperium and perinatal conditions | 1/112 |
| ColitisGastrointestinal disorders | 1/209 |
| Peritonsillar abscessInfections and infestations | 1/209 |
| Humerus fractureInjury, poisoning and procedural complications | 1/209 |
| Alanine aminotransferase increasedInvestigations | 1/209 |
| Aspartate aminotransferase increasedInvestigations | 1/209 |
| Event | Brexpiprazole |
|---|---|
| Weight increasedInvestigations | 22/209 |
| HeadacheNervous system disorders | 18/209 |
| InsomniaPsychiatric disorders | 17/209 |
| Age, Categorical(Participants) | Brexpiprazole |
|---|---|
| <=18 years | 1 |
| Between 18 and 65 years | 208 |
| >=65 years | 1 |
| Age, Continuous(years) | Brexpiprazole |
|---|---|
| Mean | 40.89 ± 11.35 |
| Sex: Female, Male(Participants) | Brexpiprazole |
|---|---|
| Female | 113 |
| Male | 97 |
| Region of Enrollment(participants) | Brexpiprazole |
|---|---|
| United States | 50 |
| Ukraine | 64 |
| Slovakia | 1 |
| Serbia | 19 |
| Russian Federation | 52 |
| Estonia | 6 |
| Poland | 9 |
| Romania | 9 |
The record gives a start of Jul 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole